# OnCo record paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026" ;
  schema:name "MATRix/IELSG43: high-dose chemotherapy and autologous stem cell transplant versus non-myeloablative consolidation in primary CNS lymphoma"@en ;
  schema:description "In the largest trial ever run in lymphoma of the brain, a stem cell transplant after MATRix chemotherapy kept 78 percent of patients free of progression at three years against 51 percent with conventional consolidation chemotherapy, and lengthened survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(26)00917-7>, <https://pubmed.ncbi.nlm.nih.gov/42486133/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(26)00917-7> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Illerhaus G, Ferreri AJM, Wendler J, et al." ;
  onco:cancers <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/carmustine/> ;
  onco:trials <https://onco.cc/trials/ielsg43/> ;
  onco:journals <https://onco.cc/journals/lancet/> .